◈ Nootpedia
Extended Research →
Verdict, decision matrix, deep dives, sourcing notes & full sources

Armodafinil

Well Researched

R-enantiomer-only modafinil with smoother monophasic decline, ~33-40% higher AUC mg-for-mg, and Tmax 3-4 hr later than racemic modafinil. | Pharmaceutical · Oral

Aliases (5)
Nuvigil · Waklert · Artvigil · R-modafinil · R-(−)-modafinil
TYPICAL DOSE
150 mg
ROUTE
Oral (tablet)
CYCLE
5 days/week
STORAGE
Room temp; original container
✎
Did you know? You can suggest edits to improve this compound's information.
Submitted via email — no account required.
Suggest an edit
▸Brand options4 known
NuvigilWaklertArtvigilR-modafinil

StatusSchedule IV (US, DEA); Prescription-only (EU, UK, AU, CA)

▸ Overview TL;DR

R-enantiomer-only modafinil with smoother monophasic decline, ~33-40% higher AUC mg-for-mg, and Tmax 3-4 hr later than racemic modafinil. 150 mg armodafinil ≈ 200 mg modafinil clinically but feels different — less peak, longer tail. For Dylan's late chronotype, the long tail is a double-edged sword: better sustained 6 PM cognition, but real risk of pushing sleep past 1 AM during midnight-migration window.

▸ Mechanism of action

Armodafinil is the R-(−)-enantiomer of racemic modafinil. R-modafinil is the pharmacologically active half — it is the source of modafinil's wake-promoting and psychotropic effects. The S-enantiomer in racemic modafinil clears 3-4× faster and contributes minimally to sustained efficacy.

Mechanism (same as modafinil core):

  • Weak dopamine transporter (DAT) inhibitor — competitive binding raises extracellular DA in striatum and prefrontal cortex without causing the sharp DA spikes seen with amphetamines or methylphenidate. This atypical DAT-inhibition profile is why modafinil family has low addiction liability.
  • Indirect orexin/hypocretin activation — R-modafinil does not bind orexin receptors directly, but raises orexinergic tone via D1 receptor activation in lateral hypothalamus, where dopaminergic fibers surround orexin neurons.
  • Indirect histamine release — orexin neurons project to tuberomammillary nucleus histamine neurons; modafinil-induced wakefulness requires intact orexin neurons to elevate histamine.
  • Glutamatergic potentiation — produces long-term potentiation of glutamatergic transmission in cortex.
  • Mild norepinephrine + serotonin effects — secondary to the multi-system arousal cascade.

The wakefulness pathway is essentially: DAT inhibition → D1 activation in lateral hypothalamus → orexin release → histamine + glutamate cascade → cortical arousal. This multi-system, indirect approach is why modafinil family promotes wakefulness without the receptor-flooding effects of classical stimulants.

▸ Pharmacokinetics No data
Pharmacokinetics data not available for this compound.
No half-life mentions found in the source notes.
▸Research indications5 use cases

Weak dopamine transporter (DAT) inhibitor

Most effective

competitive binding raises extracellular DA in striatum and prefrontal cortex without causing the sharp DA spikes seen with amphetamines …

Indirect orexin/hypocretin activation

Effective

R-modafinil does not bind orexin receptors directly, but raises orexinergic tone via D1 receptor activation in lateral hypothalamus, wher…

Indirect histamine release

Effective

orexin neurons project to tuberomammillary nucleus histamine neurons; modafinil-induced wakefulness requires intact orexin neurons to ele…

Glutamatergic potentiation

Moderate

produces long-term potentiation of glutamatergic transmission in cortex.

Mild norepinephrine + serotonin effects

Moderate

secondary to the multi-system arousal cascade.

▸Research protocols1 protocols
GoalDoseFrequencySoloCycle
Do not redose later in the day————

Auto-extracted from dosing notes. For full context including caveats and Dylan-specific protocols, see the Dosing protocols section.

▸Quality indicators4 checks
✓
FDA-approved manufacturer
NDC code on the bottle matches FDA registration. Generic OK; backyard not OK.
✓
Brand vs generic listed
Pharmacy fills should disclose substitution. AB-rated generics are bioequivalent.
✓
Tamper-evident packaging
Pharmacy seal intact, lot number + expiry visible on the bottle and the box.
!
Schedule labeling correct
C-II / C-IV warnings on label match the medication; report any mismatch to the pharmacist.
▸ What to expect Generic
  1. 1
    Day 1
    PK-driven acute peak per administration. Verify dose tolerated.
  2. 2
    Week 1
    Steady-state reached for most daily-dosed pharma.
  3. 3
    Week 2-4
    Therapeutic effect established; titration window if needed.
  4. 4
    Long-term
    Periodic monitoring per drug class (labs, BP, ECG as applicable).
▸ Side effects + safety Tabbed view

Common (>10% users)

  • Headache (~25-30% incidence; often first-dose, fades after 1-2 weeks)
  • Insomnia/sleep disturbance (~14% in 12-month data; higher in late-day dosing)
  • Nausea (~5-10%)
  • Dizziness (~5%)
  • Dry mouth / xerostomia (~5-10%)

Less common (1-10%)

  • Anxiety / irritability
  • Decreased appetite
  • Diarrhea
  • Palpitations / mild HR elevation (~6-7 bpm average)
  • Mild BP elevation (~3-4 mmHg systolic, ~2 mmHg diastolic)
  • Depression (more frequent at 250 mg vs 150 mg per drugs.com side effect data)
▸Interactions11 compounds
  • caffeineSynergistic
    (low dose, 50-100 mg): Adenosine antagonism is mechanistically additive to dopamine/orexin/histamine arousal. Dylan baseline has zero caffeine, so 50 mg with…
  • L-theanine 200 mgSynergistic
    Smooths the alerting edge, no efficacy compromise.
  • bromantaneSynergistic
    Different mechanism (mild DA + 5-HT + DAT, anti-asthenic). Stacks cleanly per Russian eugeroic protocols. This is part of Dylan's V5 plan.
  • citicoline / Alpha-GPCSynergistic
    Cholinergic substrate support for the cognitive load that modafinil-class drugs let you sustain.
  • bupropionSynergistic
    (if Rx-path): 6 RCTs back modafinil + bupropion for depression/fatigue; same mechanism logic applies to armodafinil + bupropion.
  • omega-3 / DHASynergistic
    General brain substrate; no interaction.
  • MAOIs (selegiline >10 mg, tranylcypromine, phenelzine):Avoid
    Hypertensive crisis risk. Note for Dylan: Selegiline 1-2.5 mg/day is MAO-B selective only and clinically considered safe with modafinil-class drugs, but stay…
  • classical stimulants (amphetamine, methylphenidate, focalin):Avoid
    Stacking dopaminergic stimulants → overstimulation, cardiovascular load, anxiety, sleep wreck. Pick one.
  • 9-Me-BC + bromantane + armodafinil triple-stack:Avoid
    3 dopaminergic agents = overstimulation risk per encyclopedia.
  • other eugeroics (modafinil, solriamfetol, pitolisant):Avoid
    Redundant + AUC stacking. Pick one wakefulness anchor.
  • hormonal contraceptives (irrelevant for Dylan, but flag):Avoid
    CYP3A4 induction reduces effectiveness ~18%.
▸References28 sources

Darwish et al. 2009 — Armodafinil and Modafinil Have Substantially Different Pharmacokinetic Profiles Despite Having the Same Terminal Half-Lives (PMID 19663523)

2009

pooled analysis of 3 RCT PK studies; 33-40% AUC difference established

pubmed.ncbi.nlm.nih.govView →

Darwish et al. 2010 — PK of armodafinil and modafinil in OSA crossover study (PMID 21118743)

2010

single + multiple dose; armodafinil 200 AUC vs modafinil 200 AUC; monophasic vs biphasic decline

pubmed.ncbi.nlm.nih.govView →

Darwish et al. 2009 — Pharmacokinetic Profile of Armodafinil in Healthy Subjects (PMID 19133704)

2009

pooled healthy-subject PK; Tmax, Cmax, food effect

pubmed.ncbi.nlm.nih.govView →

Tembe et al. 2011 — Armodafinil 150 vs Modafinil 200 in shift work disorder RCT (PMID 21766023)

2011

clinical equipotency confirmed

pubmed.ncbi.nlm.nih.govView →

Black et al. 2010 — Long-term tolerability and efficacy of armodafinil 12-month open-label extension (JCSM)

2010

n=743, no tolerance, AE profile, BP/HR effects plateau by month 3

jcsm.aasm.orgView →
Was this helpful?
Your feedback shapes what we research deeper.
Continue: Extended Research →
Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from Armodafinil
Modafinil
PRIMARY-PICK
Eugeroic — wakefulness-promoting agent (atypical CNS stimulant)
HIGH
Adrafinil
SKIP-PERMANENT
Eugeroic — modafinil prodrug
HIGH
THN102
SKIP-FOR-NOW
Fixed-dose combination eugeroic — modafinil + astroglial connexin 30 (Cx30) inhibitor (subtherapeutic flecainide)
HIGH
Solriamfetol
WATCH-LIST
DNRI (dopamine + norepinephrine reuptake inhibitor) — wakefulness-promoting agent; secondary TAAR1 + 5-HT1A agonism (preclinical)
MEDIUM
Concerta
SKIP-FOR-NOW
Methylphenidate-class — racemic methylphenidate in osmotic-release oral system (OROS) extended-release tablet (Janssen / ALZA elementary osmotic pump technology)
MEDIUM
Guanfacine
SKIP-FOR-NOW
Selective α2A-adrenergic receptor agonist (centrally-acting antihypertensive / ADHD non-stimulant)
HIGH
Pitolisant
SKIP-FOR-NOW
Histamine H3 receptor inverse agonist / antagonist — first-in-class wakefulness-promoting agent (non-stimulant, non-controlled)
MEDIUM
Propranolol
OPTIONAL-ADD
Non-selective beta-adrenergic blocker (β1 + β2 antagonist)
HIGH
Vyvanse
SKIP-FOR-NOW
Amphetamine prodrug — long-acting d-amphetamine delivered via L-lysine peptide bond, cleaved by RBC aminopeptidase
MEDIUM

More in Pharmaceutical · Oral

89 compounds in bucket
3-n-Butylphthalide (NBP)
OPTIONAL-ADD
Plant-derived multi-target neuroprotectant (phthalide; originally isolated from celery seed Apium graveolens); approved Chinese pharmaceutical for acute ischemic stroke
LOW
9-Methyl-β-carboline
WATCH-LIST
β-carboline alkaloid (tricyclic pyridoindole) — multimodal dopaminergic neurorestorative + dual MAO-A/B inhibitor + neurotrophic-factor inducer
LOW
ACD-856
WATCH-LIST
Pan-Trk receptor positive allosteric modulator (Trk-PAM) — small-molecule triazinetrione
HIGH
Adderall
SKIP-FOR-NOW
Amphetamine — substituted phenethylamine releasing agent (SNDRA)
MEDIUM
Adrafinil
SKIP-PERMANENT
Eugeroic — modafinil prodrug
HIGH
AF710B
SKIP-FOR-NOW
Dual-mechanism small molecule — M1 muscarinic positive allosteric modulator (PAM) + sigma-1 receptor agonist
HIGH